B

Baroness Merron (Lab)

Speaking in the House of Lords on 22 October 2026

Debate

Hormone Replacement Therapy: Product Shortage

Contribution

It is a priority for sure. On the point the noble Baroness raised on HRT, there were significant supply pressures in 2022, but that has been contained. I am glad that we are approaching this as we approach other shortages elsewhere; for example, through protocols. As I have explained, there are alternatives. I understand the concerns it might generate, but it is important that we advise women—for whom, I agree, this is crucial—that a range of products and formulations are available, and pharmacists and GPs are well able to assist and ensure that they do not go without their medication.

More from Baroness Merron (Lab)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.